TMC125 Showed Significant Virologic Response at Week 24 in
Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3
Trials
Data Published in The Lancet on TMC125, an Investigational NNRTIfrom Tibotec YARDLEY, Pa., July 05, 2007 /PRNewswire/ -- Data from twoongoing Phase 3 studies (DUET-1 and DUET-2) showed significantlymore HIV-1 adult patients with documented non-nucleoside reversetranscriptase inhibitor (NNRTI) and protease inhibitor (PI)resistance reached an undetectable viral load (defined as achievingco...
New Clinical Study Results Indicate Higher Early Virologic Response
with Celgosivir Combination Therapy in HCV Non-Responders
Data to be Presented April 15th at EASL Conference in Barcelona,Spain VANCOUVER and SAN DIEGO, CA, April 11, 2007/PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developerof drugs for infectious diseases, has received new top-line resultsconfirming the previously announced clinical results (November 6,2006) indicating evidence of clinical benefit, safety andtolerability in a Phas...